Process of Treating Myopia by Modulating Retinal Signaling Pathways Underlying Retinal Response to Positive and Negative Optical Defocus

Myopia (nearsightedness) is the most common eye disorder, and is rapidly becoming one of the leading causes of blindness.  At the current rate of myopia occurrences, more than half the population will be myopic by 2050.  While myopia has already increased from effecting 25% of the U.S. to 58% as of 2014, over 80% of the populations of urban communities are already myopic.  Current treatments are inadequate to combat this pending potential health crisis, however, this unprecedented research may solve this issue through drug development aimed to modulate eye growth and reduce myopia progression safely and effectively.

Patent Information:
Technology/Start-up ID: